Ted R Hupp

List of Publications by Year
in descending order

134 papers	7,914 citations	81900 39 h-index	53230 85 g-index
137 all docs	137 docs citations	137 times ranked	14365 citing authors

#	Article	IF	Citations
1	The Role of IFITM Proteins in Tick-Borne Encephalitis Virus Infection. Journal of Virology, 2022, 96, JVI0113021.	3.4	14
2	Mesenchymal stem cells transfer mitochondria to allogeneic Tregs in an HLA-dependent manner improving their immunosuppressive activity. Nature Communications, 2022, 13, 856.	12.8	22
3	DIA-MS proteome analysis of formalin-fixed paraffin-embedded glioblastoma tissues. Analytica Chimica Acta, 2022, 1204, 339695.	5.4	10
4	Self-derived peptides from the SARS-CoV-2 spike glycoprotein disrupting shaping and stability of the homotrimer unit. Biomedicine and Pharmacotherapy, 2022, 151, 113190.	5.6	0
5	Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes. ACS Chemical Biology, 2022, 17, 1876-1889.	3.4	11
6	The Elephant Evolved p53 Isoforms that Escape MDM2-Mediated Repression and Cancer. Molecular Biology and Evolution, 2022, 39, .	8.9	9
7	Hydrogen deuterium exchange mass spectrometry identifies the dominant paratope in CD20 antigen binding to the NCD1.2 monoclonal antibody. Biochemical Journal, 2021, 478, 99-120.	3.7	3
8	Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages. Biomolecules, 2021, 11, 297.	4.0	20
9	The effects of RNA editing in cancer tissue at different stages in carcinogenesis. RNA Biology, 2021, 18, 1-16.	3.1	15
10	Reflux of Endoplasmic Reticulum proteins to the cytosol inactivates tumor suppressors. EMBO Reports, 2021, 22, e51412.	4.5	17
11	Interfaces with Structure Dynamics of the Workhorses from Cells Revealed through Cross-Linking Mass Spectrometry (CLMS). Biomolecules, 2021, 11, 382.	4.0	8
12	Functional Interfaces, Biological Pathways, and Regulations of Interferon-Related DNA Damage Resistance Signature (IRDS) Genes. Biomolecules, 2021, 11, 622.	4.0	18
13	Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1-Linked Functions Crosstalk. Protein and Peptide Letters, 2021, 28, 340-358.	0.9	0
14	Identification of a Stable, Non-Canonically Regulated Nrf2 Form in Lung Cancer Cells. Antioxidants, 2021, 10, 786.	5.1	5
15	An Ultrasensitive Biosensor for Detection of Femtogram Levels of the Cancer Antigen AGR2 Using Monoclonal Antibody Modified Screen-Printed Gold Electrodes. Biosensors, 2021, 11, 184.	4.7	7
16	An integrated DNA and RNA variant detector identifies a highly conserved three base exon in the MAP4K5 kinase locus. RNA Biology, 2021, 18, 2556-2575.	3.1	1
17	CHIP-dependent regulation of the actin cytoskeleton is linked to neuronal cell membrane integrity. IScience, 2021, 24, 102878.	4.1	6
18	Comparison of different digestion methods for proteomic analysis of isolated cells and FFPE tissue samples. Talanta, 2021, 233, 122568.	5.5	9

#	Article	IF	Citations
19	Structural determinants of peptide-dependent TAP1-TAP2 transit passage targeted by viral proteins and altered by cancer-associated mutations. Computational and Structural Biotechnology Journal, 2021, 19, 5072-5091.	4.1	9
20	Kinomics platform using GBM tissue identifies BTK as being associated with higher patient survival. Life Science Alliance, 2021, 4, e202101054.	2.8	4
21	Molecular Determinants and Specificity of mRNA with Alternatively-Spliced UPF1 Isoforms, Influenced by an Insertion in the â€˜Regulatory Loopâ€™. International Journal of Molecular Sciences, 2021, 22, 12744.	4.1	7
22	The anterior gradient-2 interactome. American Journal of Physiology - Cell Physiology, 2020, 318, C40-C47.	4.6	30
23	The effects of p53 gene inactivation on mutant proteome expression in a human melanoma cell model. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129722.	2.4	4
24	A blocking antibody against canine CSF-1R maturated by limited CDR mutagenesis. Antibody Therapeutics, 2020, 3, 193-204.	1.9	2
25	The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276. Cellular and Molecular Biology Letters, 2020, 25, 41.	7.0	14
26	Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site. Journal of Clinical Medicine, 2020, 9, 1473.	2.4	73
27	High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery. SLAS Discovery, 2020, 25, 770-782.	2.7	22
28	Analysis of venom sac constituents from the solitary, aculeate wasp Cerceris rybyensis. Toxicon, 2019, 169, 1-4.	1.6	5
29	Control of anterior <scp>GR</scp> adient 2 (<scp>AGR</scp> 2) dimerization links endoplasmic reticulum proteostasis to inflammation. EMBO Molecular Medicine, 2019, 11, .	6.9	48
30	Regulation of the Expression of DAPK1 by SUMO Pathway. Biomolecules, 2019, 9, 151.	4.0	6
31	An inter-subunit protein-peptide interface that stabilizes the specific activity and oligomerization of the AAA+ chaperone Reptin. Journal of Proteomics, 2019, 199, 89-101.	2.4	3
32	The effects of IFITM1 and IFITM3 gene deletion on IFNÎ³ stimulated protein synthesis. Cellular Signalling, 2019, 60, 39-56.	3.6	19
33	Discovering Putative Protein Targets of Small Molecules: A Study of the p53 Activator Nutlin. Journal of Chemical Information and Modeling, 2019, 59, 1529-1546.	5.4	15
34	Insights into the Effects of Cancer Associated Mutations at the UPF2 and ATP-Binding Sites of NMD Master Regulator: UPF1. International Journal of Molecular Sciences, 2019, 20, 5644.	4.1	13
35	Copy number variation: A prognostic marker for young patients with squamous cell carcinoma of the oral tongue. Journal of Oral Pathology and Medicine, 2019, 48, 24-30.	2.7	20
36	An Integrative â€œOmicsâ€•Approach, for Identification of Bona Fides PLK1 Associated Biomarker in Esophageal Adenocarcinoma. Current Cancer Drug Targets, 2019, 19, 742-755.	1.6	1

#	Article	IF	Citations
37	The Sequence-specific Peptide-binding Activity of the Protein Sulfide Isomerase AGR2 Directs Its Stable Binding to the Oncogenic Receptor EpCAM. Molecular and Cellular Proteomics, 2018, 17, 737-763.	3.8	16
38	Monoâ€Substituted Hydrocarbon Diastereomer Combinations Reveal Stapled Peptides with High Structural Fidelity. Chemistry - A European Journal, 2018, 24, 2094-2097.	3.3	6
39	Evidence for allosteric effects on p53 oligomerization induced by phosphorylation. Protein Science, 2018, 27, 523-530.	7.6	7
40	An allostatic mechanism for M2 pyruvate kinase as an amino-acid sensor. Biochemical Journal, 2018, 475, 1821-1837.	3.7	44
41	Quantitative Shotgun Proteomics Unveils Candidate Novel Esophageal Adenocarcinoma (EAC)-specific Proteins. Molecular and Cellular Proteomics, 2017, 16, 1138-1150.	3.8	17
42	Hammock: a hidden Markov model-based peptide clustering algorithm to identify protein-interaction consensus motifs in large datasets. Bioinformatics, 2016, 32, 9-16.	4.1	35
43	Rearrangement of mitochondrial pyruvate dehydrogenase subunit dihydrolipoamide dehydrogenase proteinâ€“protein interactions by the MDM2 ligand nutlinâ€3. Proteomics, 2016, 16, 2327-2344.	2.2	14
44	Mass spectrometry analysis of the oxidation states of the pro-oncogenic protein anterior gradient-2 reveals covalent dimerization via an intermolecular disulphide bond. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2016, 1864, 551-561.	2.3	12
45	The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine. PLoS ONE, 2016, 11, e0148366.	2.5	33
46	The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors. Frontiers in Molecular Biosciences, 2015, 2, 39.	3.5	30
47	Discovery of a novel ligand that modulates the proteinâ€“protein interactions of the AAA+ superfamily oncoprotein reptin. Chemical Science, 2015, 6, 3109-3116.	7.4	11
48	Insights into the Conformations of Three Structurally Diverse Proteins: Cytochrome c, p53, and MDM2, Provided by Variable-Temperature Ion Mobility Mass Spectrometry. Analytical Chemistry, 2015, 87, 3231-3238.	6.5	33
49	Mechanisms of anterior gradient-2 regulation and function in cancer. Seminars in Cancer Biology, 2015, 33, 16-24.	9.6	44
50	Phosphomimetic Mutation of the N-Terminal Lid of MDM2 Enhances the Polyubiquitination of p53 through Stimulation of E2-Ubiquitin Thioester Hydrolysis. Journal of Molecular Biology, 2015, 427, 1728-1747.	4.2	8
51	A systems wide mass spectrometric based linear motif screen to identify dominant in-vivo interacting proteins for the ubiquitin ligase MDM2. Cellular Signalling, 2014, 26, 1243-1257.	3.6	23
52	Evaluating DAPK as a therapeutic target. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 371-386.	4.9	41
53	Engineering a synthetic cell panel to identify signalling components reprogrammed by the cell growth regulator anterior gradient-2. Molecular BioSystems, 2014, 10, 1409-1425.	2.9	16
54	Addicted to secrete â€“ novel concepts and targets in cancer therapy. Trends in Molecular Medicine, 2014, 20, 242-250.	6.7	72

#	Article	IF	Citations
55	Quantitative Proteomic Profiling of Pleomorphic Human Sarcoma Identifies CLIC1 as a Dominant Pro-Oncogenic Receptor Expressed in Diverse Sarcoma Types. Journal of Proteome Research, 2014, 13, 2543-2559.	3.7	8
56	Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry. Proteomics, 2013, 13, 2512-2525.	2.2	28
57	Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2. Cancer Letters, 2013, 333, 187-193.	7.2	24
58	Non-degradative ubiquitination of the Notch1 receptor by the E3 ligase MDM2 activates the Notch signalling pathway. Biochemical Journal, 2013, 450, 523-536.	3.7	41
59	Development of a fluorescent monoclonal antibodyâ€based assay to measure the allosteric effects of synthetic peptides on selfâ€oligomerization of AGR2 protein. Protein Science, 2013, 22, 1266-1278.	7.6	18
60	M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5881-5886.	7.1	132
61	Nanosensing protein allostery using a bivalent mouse double minute two (MDM2) assay. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8073-8078.	7.1	22
62	Strategies for p53 Reactivation in Human Sarcoma. Cancer Cell, 2012, 22, 283-285.	16.8	9
63	An iTRAQ Proteomics Screen Reveals the Effects of the MDM2 Binding Ligand Nutlin-3 on Cellular Proteostasis. Journal of Proteome Research, 2012, 11, 5464-5478.	3.7	25
64	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
65	Concepts in MDM2 Signaling: Allosteric Regulation and Feedback Loops. Genes and Cancer, 2012, 3, 291-297.	1.9	17
66	Anterior Gradient-3: A novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models. Journal of Immunological Methods, 2012, 378, 20-32.	1.4	41
67	Exploiting the MDM2-CK1Î± Protein-Protein Interface to Develop Novel Biologics That Induce UBL-Kinase-Modification and Inhibit Cell Growth. PLoS ONE, 2012, 7, e43391.	2.5	21
68	Data-independent Proteomic Screen Identifies Novel Tamoxifen Agonist that Mediates Drug Resistance. Journal of Proteome Research, 2011, 10, 4567-4578.	3.7	42
69	Tuberous sclerosisâ€2 (TSC2) regulates the stability of deathâ€associated protein kinaseâ€1 (DAPK) through a lysosomeâ€dependent degradation pathway. FEBS Journal, 2011, 278, 354-370.	4.7	23
70	Identification of Two Reactive Cysteine Residues in the Tumor Suppressor Protein p53 Using Top-Down FTICR Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2011, 22, 888-897.	2.8	43
71	Mapping a Noncovalent Proteinâ€“Peptide Interface by Top-Down FTICR Mass Spectrometry Using Electron Capture Dissociation. Journal of the American Society for Mass Spectrometry, 2011, 22, 1432-1440.	2.8	36
72	Chemical states of the N-terminal â€œlidâ€•of MDM2 regulate p53 binding: Simulations reveal complexities of modulation. Cell Cycle, 2011, 10, 82-89.	2.6	28

#	Article	IF	Citations
73	p21^{WAF1}is component of a positive feedback loop that maintains the p53 transcriptional program. Cell Cycle, 2011, 10, 932-950.	2.6	28
74	Drug discovery and mutant p53. Trends in Cell Biology, 2010, 20, 542-555.	7.9	57
75	Deathâ€associated protein kinase (DAPK) and signal transduction. FEBS Journal, 2010, 277, 47-47.	4.7	9
76	Deathâ€associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death. FEBS Journal, 2010, 277, 48-57.	4.7	78
77	A Novel p53 Phosphorylation Site within the MDM2 Ubiquitination Signal. Journal of Biological Chemistry, 2010, 285, 37762-37772.	3.4	27
78	The molecular dynamics of MDM2. Cell Cycle, 2010, 9, 1878-1881.	2.6	18
79	A Novel p53 Phosphorylation Site within the MDM2 Ubiquitination Signal. Journal of Biological Chemistry, 2010, 285, 37773-37786.	3.4	22
80	The Effects of Phosphomimetic Lid Mutation on the Thermostability of the N-terminal Domain of MDM2. Journal of Molecular Biology, 2010, 398, 414-428.	4.2	25
81	A Divergent Substrate-Binding Loop within the Pro-oncogenic Protein Anterior Gradient-2 Forms a Docking Site for Reptin. Journal of Molecular Biology, 2010, 404, 418-438.	4.2	47
82	The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging, 2009, 1, 490-502.	3.1	109
83	Peptide Combinatorial Libraries Identify TSC2 as a Death-associated Protein Kinase (DAPK) Death Domain-binding Protein and Reveal a Stimulatory Role for DAPK in mTORC1 Signaling. Journal of Biological Chemistry, 2009, 284, 334-344.	3.4	68
84	CK1Î± Plays a Central Role in Mediating MDM2 Control of p53 and E2F-1 Protein Stability. Journal of Biological Chemistry, 2009, 284, 32384-32394.	3.4	77
85	A Function for the RING Finger Domain in the Allosteric Control of MDM2 Conformation and Activity. Journal of Biological Chemistry, 2009, 284, 11517-11530.	3.4	30
86	The alternative splice variant of DAPK-1, s-DAPK-1, induces proteasome-independent DAPK-1 destabilization. Molecular and Cellular Biochemistry, 2009, 328, 101-107.	3.1	21
87	Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif. Journal of Chemical Biology, 2009, 2, 113-129.	2.2	35
88	The Anterior Gradient-2 Pathway as a Model for Developing Peptide-Aptamer Anti-Cancer Drug Leads that Stimulate p53 Function. Current Chemical Biology, 2009, 3, 124-137.	0.5	2
89	The Anterior Gradient-2 Pathway as a Model for Developing Peptide-Aptamer Anti-Cancer Drug Leads that Stimulate p53 Function. Current Chemical Biology, 2009, 3, 124-137.	0.5	9
90	An animal model to evaluate the function and regulation of the adaptively evolving stress protein SEP53 in oesophageal bile damage responses. Cell Stress and Chaperones, 2008, 13, 375-385.	2.9	8

#	Article	IF	Citations
91	An alternative transcript from the deathâ€associated protein kinaseâ€ƒ1 locus encoding a small protein selectively mediates membrane blebbing. FEBS Journal, 2008, 275, 2574-2584.	4.7	5
92	ATP stimulates MDM2â€mediated inhibition of the DNAâ€binding function of E2F1. FEBS Journal, 2008, 275, 4875-4886.	4.7	12
93	Sensitive, Specific, and Quantitative FTICR Mass Spectrometry of Combinatorial Post-Translational Modifications in Intact Histone H4. Analytical Chemistry, 2008, 80, 4147-4153.	6.5	14
94	A Central Role for CK1 in Catalyzing Phosphorylation of the p53 Transactivation Domain at Serine 20 after HHV-6B Viral Infection. Journal of Biological Chemistry, 2008, 283, 28563-28573.	3.4	35
95	DAPK-1 Binding to a Linear Peptide Motif in MAP1B Stimulates Autophagy and Membrane Blebbing. Journal of Biological Chemistry, 2008, 283, 9999-10014.	3.4	120
96	The MDM2 Ubiquitination Signal in the DNA-Binding Domain of p53 Forms a Docking Site for Calcium Calmodulin Kinase Superfamily Members. Molecular and Cellular Biology, 2007, 27, 3542-3555.	2.3	46
97	A Germ Line Mutation in the Death Domain of DAPK-1 Inactivates ERK-induced Apoptosis. Journal of Biological Chemistry, 2007, 282, 13791-13803.	3.4	25
98	MDM2 Chaperones the p53 Tumor Suppressor*. Journal of Biological Chemistry, 2007, 282, 32603-32612.	3.4	50
99	Identification of a Dominant Negative Functional Domain on DAPK-1 That Degrades DAPK-1 Protein and Stimulates TNFR-1-mediated Apoptosis. Journal of Biological Chemistry, 2007, 282, 16792-16802.	3.4	32
100	Microarray-Formatted Clinical Biomarker Assay Development Using Peptide Aptamers to Anterior Gradient-2. Biochemistry, 2007, 46, 13742-13751.	2.5	33
101	Multienzyme assembly of a p53 transcription complex. Nature Structural and Molecular Biology, 2007, 14, 885-887.	8.2	11
102	Adaptive Evolution of a Stress Response Protein. PLoS ONE, 2007, 2, e1003.	2.5	11
103	On the Mechanism of Sequence-specific DNA-dependent Acetylation of p53: The Acetylation Motif is Exposed upon DNA Binding. Journal of Molecular Biology, 2006, 357, 442-456.	4.2	23
104	Dual-Site Regulation of MDM2 E3-Ubiquitin Ligase Activity. Molecular Cell, 2006, 23, 251-263.	9.7	165
105	Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo. Biochemical Journal, 2006, 397, 355-367.	3.7	28
106	The calcium-binding domain of the stress protein SEP53 is required for survival in response to deoxycholic acid-mediated injury. FEBS Journal, 2006, 273, 1930-1947.	4.7	28
107	CK2-site Phosphorylation of p53 is Induced in Î”Np63 Expressing Basal Stem Cells in UVB Irradiated Human Skin. Cell Cycle, 2006, 5, 2489-2494.	2.6	22
108	The N-terminal Interferon-binding Domain (IBiD) Homology Domain of p300 Binds to Peptides with Homology to the p53 Transactivation Domain. Journal of Biological Chemistry, 2004, 279, 49395-49405.	3.4	14

#	Article	IF	Citations
109	Interferon Regulatory Factor 1 Binding to p300 Stimulates DNA-Dependent Acetylation of p53. Molecular and Cellular Biology, 2004, 24, 10083-10098.	2.3	71
110	The Barrettâ€™s Antigen Anterior Gradient-2 Silences the p53 Transcriptional Response to DNA Damage. Molecular and Cellular Proteomics, 2004, 3, 534-547.	3.8	136
111	Expansion of Protein Interaction Maps by Phage Peptide Display Using MDM2 as a Prototypical Conformationally Flexible Target Protein. Journal of Molecular Biology, 2004, 337, 129-145.	4.2	31
112	Intrasteric regulation of MDM2. Trends in Biochemical Sciences, 2003, 28, 346-349.	7.5	28
113	Drug discovery and p53. Drug Discovery Today, 2003, 8, 347-355.	6.4	88
114	DNA-dependent Acetylation of p53 by the Transcription Coactivator p300. Journal of Biological Chemistry, 2003, 278, 13431-13441.	3.4	97
115	The Proline Repeat Domain of p53 Binds Directly to the Transcriptional Coactivator p300 and Allosterically Controls DNA-Dependent Acetylation of p53. Molecular and Cellular Biology, 2003, 23, 8846-8861.	2.3	97
116	Signaling to p53: The Use of Phospho-Specific Antibodies to Probe for In Vivo Kinase Activation. , 2003, 234, 171-202.		13
117	The Conformationally Flexible S9â€“S10 Linker Region in the Core Domain of p53 Contains a Novel MDM2 Binding Site Whose Mutation Increases Ubiquitination of p53 in Vivo. Journal of Biological Chemistry, 2002, 277, 28446-28458.	3.4	103
118	The human oesophageal squamous epithelium exhibits a novel type of heat shock protein response. FEBS Journal, 2001, 268, 5343-5355.	0.2	42
119	Inhibition of p53â€dependent transcription by BOXâ€phosphoâ€peptide mimetics that bind to p300. EMBO Reports, 2001, 2, 139-144.	4.5	94
120	Stoichiometric Phosphorylation of Human p53 at Ser315Stimulates p53-dependent Transcription. Journal of Biological Chemistry, 2001, 276, 4699-4708.	3.4	84
121	Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene, 2000, 19, 3829-3839.	5.9	62
122	Development of Physiological Models to Study Stress Protein Responses. , 2000, 99, 465-483.		6
123	p53-Dependent growth arrest and altered p53-immunoreactivity following metabolic labelling with 32P ortho-phosphate in human fibroblasts. Oncogene, 1999, 18, 3788-3792.	5.9	43
124	Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation. Oncogene, 1999, 18, 6305-6312.	5.9	41
125	Biochemical characterization of different conformational states of the Sf9 cell-purified p53His175 mutant protein. FEBS Letters, 1999, 463, 179-184.	2.8	13
126	Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochemical Journal, 1999, 342, 133-141.	3.7	135

#	Article	IF	Citations
127	Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochemical Journal, 1999, 342, 133.	3.7	57
128	DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene, 1998, 17, 1045-1052.	5.9	110
129	Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential. Oncogene, 1997, 15, 237-244.	5.9	48
130	Regulating and replacing suppressor gene function with small synthetic molecules; design of an active synthetic suppressor protein. Biochemical Society Transactions, 1996, 24, 592S-592S.	3.4	0
131	Allosteric Regulation of the Thermostability and DNA Binding Activity of Human p53 by Specific Interacting Proteins. Journal of Biological Chemistry, 1996, 271, 3917-3924.	3.4	88
132	Two Distinct Signaling Pathways Activate the Latent DNA Binding Function of p53 in a Casein Kinase II-independent Manner. Journal of Biological Chemistry, 1995, 270, 18165-18174.	3.4	96
133	Allosteric activation of latent p53 tetramers. Current Biology, 1994, 4, 865-875.	3.9	304
134	Dominant Steady State Proteome Changes in the Absence of CHIP Highlight a Role in Neuronal Cell Membrane Integrity Linked to the Actin Cytoskeleton. SSRN Electronic Journal, 0, , .	0.4	0